Suchergebnisse
Suchergebnisse:
MEMENTO BELLI NEC ULTRA ADDAS LOQUI NON QUASI CRUDELIS ! PAULATIM EXPELLAM EOS . . . DONEC AUGEARIS ET POSSIDEAS TERRAM VOS ESTIS DII !!!
Gradalis is a late stage biotechnology company focused on the development and commercialization of novel personalized therapeutics to treat cancer. We are developing Vigil, our proprietary immunotherapy platform in multiple advanced cancer indications with the lead program for the treatment of patients with Ewing's sarcoma.
John Nemunaitis, MD. John is a co-founder and Chief Scientific Officer at Gradalis. He has served in various roles since helping co-found the company in 2003. He specializes in medical oncology and hematology and is board certified in internal medicine.
Company profile page for Gradalis Inc including stock price, company news, executives, board members, and contact information
- 4
First published at 17:58 UTC on November 22nd, 2018.
Gradalis, Inc. | 957 followers on LinkedIn. Leading a new way to fight cancer | Gradalis is a late-stage clinical biotechnology company developing immunotherapies for multiple cancer indications ...
Clinical trials are research investigations in which people volunteer to test new treatments, interventions or tests as a means to prevent, detect, treat or manage various diseases or medical conditions. Vigil is a fully personalized cancer immunotherapy utilizing genetically modified tumor cells.
